DA 9701

Drug Profile

DA 9701

Alternative Names: DA-9701; Motilitone

Latest Information Update: 24 Aug 2016

Price : $50

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Dong-A Pharmaceutical; Dong-A ST
  • Class Phytotherapies
  • Mechanism of Action Motilin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Dyspepsia

Highest Development Phases

  • Marketed Non-ulcer dyspepsia

Most Recent Events

  • 22 Jan 2016 Preclinical trials in Non-ulcer dyspepsia in China (PO) before January 2016 (Dong-A ST Pipeline, January 2016)
  • 01 Mar 2015 Phase-II clinical trials in Non-ulcer dyspepsia in USA (PO) (NCT02365701)
  • 24 Feb 2015 Dong-A Pharmaceutical plans a phase II trial for Non-ulcer dyspepsia in USA (NCT02365701)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top